GT Biopharma (FRA:OXIA) PB Ratio: 25.65 (As of Jul. 13, 2026)


FRA:OXIA GT Biopharma Inc FRA:OXIA
28 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma PB Ratio?

GT Biopharma FRA:OXIA 28 PB Ratio is 25.65 as of Jul. 13, 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,231 Biotechnology companies, GT Biopharma ranks better than 64.34% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-13), GT Biopharma's share price is €4.77. GT Biopharma's Book Value per Share for the quarter that ended in Mar. 2026 was €0.19. Hence, GT Biopharma's PB Ratio of today is 25.65.

The historical rank and industry rank for GT Biopharma's PB Ratio or its related term are showing as below:

FRA:OXIA' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.98
Current: 1.98

During the past 13 years, GT Biopharma's highest PB Ratio was 1.98. The lowest was 0.00. And the median was 0.00.

FRA:OXIA's PB Ratio is ranked better than
64.34% of 1231 companies
in the Biotechnology industry
Industry Median: 2.93 vs FRA:OXIA: 1.98

During the past 3 years, the average Book Value Per Share Growth Rate was -72.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of GT Biopharma was 122.30% per year. The lowest was -164.50% per year. And the median was -13.65% per year.

Back to Basics: PB Ratio


GT Biopharma  (FRA:OXIA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


GT Biopharma PB Ratio Related Terms


GT Biopharma PB Ratio Historical Data

* Premium members only.

The historical data trend for GT Biopharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma PB Ratio Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.53 2.64 1.35 0.00 24.59

GT Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.30 11.30 24.59 25.65

FRA:OXIA vs INTI, HIND, TPST: PB Ratio Comparison

For the Biotechnology subindustry, GT Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where GT Biopharma's PB Ratio falls into.


FRA:OXIA
28GF Score
GT Biopharma Inc FRA:OXIA
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

GT Biopharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=4.77/0.186
=25.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 25.65 mean?
GT Biopharma (FRA:OXIA) has a PB Ratio of 25.65 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GT Biopharma and its competitors. According to the industry distribution chart, GT Biopharma ranks #439 out of 1231 companies in the Biotechnology industry, placing it in the top 35.7%.
Is GT Biopharma's PB Ratio too high?
GT Biopharma's current PB Ratio is 25.65. The Biotechnology industry median PB Ratio is 2.93. GT Biopharma's value of 25.65 is 775.4% above this industry median. Based on the distribution chart, GT Biopharma ranks #439 out of 1231 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GT Biopharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's PB Ratio compare to INTI and HIND?
According to the Biotechnology industry distribution chart, GT Biopharma ranks #439 out of 1231 companies for PB Ratio. This puts GT Biopharma in the upper half of its industry. The industry median PB Ratio is 2.93. GT Biopharma's value of 25.65 is 775.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GT Biopharma's current PB Ratio of 25.65 is 775.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GT Biopharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GT Biopharma's current PB Ratio is 25.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current PB Ratio of 25.65. The current PB Ratio is 25.65 and 775.4% above the Biotechnology industry median of 2.93. GT Biopharma's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current PB Ratio is 25.65 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
28GF Score

Get the complete analysis for FRA:OXIA

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price